Greenwich Lifesciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Greenwich LifeSciences reported increased net losses and cash burn in Q3 2025, driven by higher R&D and administrative costs, while continuing its Phase III breast cancer immunotherapy trial.
NASDAQ
Greenwich LifeSciences reported a significantly wider net loss in Q2 2025, driven by increased R&D and administrative expenses, while also disclosing substantial doubt about its ability to continue as a going concern.
NASDAQ
10-Q: Greenwich LifeSciences Reports Q1 2025 Results, Cites Ongoing Clinical Trial and ATM Offerings
Greenwich LifeSciences reports a net loss for Q1 2025, driven by increased research and development and general and administrative expenses, while continuing to advance its Phase III clinical trial and utilize at-the-market (ATM) offerings for financing.
NASDAQ
Greenwich LifeSciences reported its Q3 2024 financial results, highlighting increased research and development expenses and a net loss, while also detailing recent equity sales and a new ATM agreement.
NASDAQ
10-Q: Greenwich LifeSciences Reports Increased R&D Spending in Q2 2024 Amidst Clinical Trial Expansion
Greenwich LifeSciences' Q2 2024 report reveals a significant increase in research and development expenses as the company expands its Phase III clinical trial for a breast cancer immunotherapy.
NASDAQ
Greenwich LifeSciences reported a net loss of $2.47 million for the first quarter of 2024, driven by increased research and development expenses.